#ezetimibe

LOGO PED - Semantic Tags by aéPiot

@logo-ped.bsky.social

2 months ago

Cabildo Abierto Una plataforma para discutir en serio, hecha en Argentina.

cabildoabierto.ar/perfil/logo-ped.bsky.social

How Free Backlinks from aéPiot Can Improve Your Post’s Authority
#JOE #GUY #CRICKETER
aepiot.ro/advanced-sea...
#EZETIMIBE #SIMVASTATIN
aepiot.ro/advanced-sea...

aepiot.com

Thiard News@F4F

@newsen.bsky.social

6 months ago

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Management The European Medicines Agency has accepted the application for Obicetrapib and its combination with Ezetimibe, marking a potential breakthrough in managing high cholesterol.

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Thiard News@F4F

@newsen.bsky.social

6 months ago

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Treatment Menarini Group's Obicetrapib and its combination with Ezetimibe have been accepted for review by the EMA for treating patients with high cholesterol.

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Thiard News@F4F

@newsen.bsky.social

6 months ago

Menarini Group's Obicetrapib and Ezetimibe Await EMA Approval for Cholesterol Management Menarini Group's applications for Obicetrapib and Ezetimibe have been accepted for review by the EMA, offering new hope for cholesterol management.

Menarini Group's Obicetrapib and Ezetimibe Await EMA Approval for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Springer Medicine

@springermedicine.com

9 months ago

Obicetrapib–ezetimibe combo reduces LDL in patients at high atherosclerosis risk Obicetrapib plus ezetimibe for 12 weeks reduced LDL cholesterol by almost 50% in people with or at high risk for atherosclerotic cardiovascular disease.

#MedNews - Obicetrapib plus #ezetimibe for 12 weeks reduced LDL cholesterol by almost 50% in people with or at high risk for #ASCVD.

Full story 👉 buff.ly/WFQx2Yx

#CardioSky #obicetrapib

JACC Journals

@jaccjournals.bsky.social

10 months ago

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry:

Myocardial infarction care pathways should implement early combination therapy with statins and #ezetimibe as standard care, because delaying use of combination LLT or using high-intensity statin monotherapy is associated with avoidable harm. www.jacc.org/doi/10.1016/...

#JACC #cvMI #SWEDEHEART

The Pharmaceutical Journal

@pharmaj.bsky.social

11 months ago

Earlier treatment with combination of drugs could prevent 5,000 heart attacks per decade, study results suggest Around 5,000 heart attacks could be prevented in the UK every decade by treating patients with a combination of statins and the cholesterol-lowering drug ezetimibe sooner after a heart attack, study…

Researchers estimate that 5,000 heart attacks could be prevented in the UK every decade by treating patients with a combination of statins and ezetimibe sooner after a heart attack, following analysis of data from 36,000 patients

#cardiology #statins #ezetimibe
buff.ly/DjN5rgy

Prof. Maciej Banach

@maciejbanach.bsky.social

11 months ago

Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Associ... Lipid disorders are the most common risk factor for atherosclerotic cardiovascular disease (ASCVD) in Poland, where it is responsible for up to 200,000 deaths per year, with the number of myocardial i...

#Rosuvastatin-based #combination treatment with acetylsalicylic acid or #ezetimibe in the management of patients at high and very high #cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025. #PoLA

www.archivesofmedicalscience.com/Rosuvastatin...

Journal of Internal Medicine

@jinternmed.bsky.social

1 year ago

New Editorial to read! The combination of #statin and #ezetimibe is safe, effective, and preferable.

➡️ Should be used in broader patient groups
➡️ Important results when treating elderly patients

🔗 doi.org/10.1111/joim.20070

➡️ Commenting on: doi.org/10.1111/joim.20029

#Cardiovascular

Thomas Agoritsas

@thomasagoritsas.bsky.social

1 year ago

Have you checked our risk-stratified #RapidRecs on #PCSK9 inhibitors and #ezetimibe for the reduction of cardiovascular events ?
@magicevidence.bsky.social @bmj.com
-->https://www.bmj.com/content/377/bmj-2021-069066

Journal of Internal Medicine

@jinternmed.bsky.social

1 year ago

New research! Moderate-intensity #statin plus #ezetimibe in elderly #ASCVD patients significantly reduces muscle symptoms compared to high-intensity statins, while achieving similar LDL-C targets.

➡️A safer, effective alternative for lipid control in seniors!

🔗 doi.org/10.1111/joim.20029

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Reports Positive Phase-3 Results for Obicetrapib and Ezetimibe Combination Therapy Menarini Group announced positive topline results from its Phase-3 studies BROADWAY and TANDEM, investigating the LDL cholesterol-lowering efficacy of Obicetrapib.

Menarini Group Reports Positive Phase-3 Results for Obicetrapib and Ezetimibe Combination Therapy #USA #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Reports Positive Phase 3 Trial Results for Obicetrapib in Lipid Management Menarini Group has announced favorable results from its Phase 3 BROADWAY and TANDEM clinical trials, focusing on the efficacy of obicetrapib in LDL cholesterol reduction.

Menarini Group Reports Positive Phase 3 Trial Results for Obicetrapib in Lipid Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe